The estimated Net Worth of Stark Richard is at least $416 Tysiąc dollars as of 15 November 2017. Stark Richard owns over 27,409 units of Angiodynamic Inc stock worth over $357,369 and over the last 13 years Stark sold ANGO stock worth over $58,571.
Stark has made over 4 trades of the Angiodynamic Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Stark exercised 27,409 units of ANGO stock worth $313,833 on 15 November 2017.
The largest trade Stark's ever made was exercising 27,409 units of Angiodynamic Inc stock on 15 November 2017 worth over $313,833. On average, Stark trades about 2,307 units every 91 days since 2012. As of 15 November 2017 Stark still owns at least 48,163 units of Angiodynamic Inc stock.
You can see the complete history of Stark Richard stock trades at the bottom of the page.
Stark's mailing address filed with the SEC is 603 QUEENSBURY AVENUE, , QUEENSBURY, NY, 12804.
Over the last 20 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman oraz Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.
founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie
Angiodynamic Inc executives and other stock owners filed with the SEC include: